Will Tesla Go Up or Down in 2025?
The last few months have been exciting for Tesla and…
Sell
43
NAMS Quote, Financials, Valuation and Earnings
Last price:
$25.92
Seasonality move
:
41.96%
Day range:
$25.71 - $26.33
52-week range:
$11.03 - $27.29
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
69.34x
P/B ratio:
6.31x
Volume:
459.5K
Avg. volume:
1.2M
1-year change:
130.89%
Market cap:
$2.4B
Revenue:
$14.1M
EPS (TTM):
-$2.25
Analysts' Opinion
-
Consensus RatingNewAmsterdam Pharma Co NV has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $43.16, NewAmsterdam Pharma Co NV has an estimated upside of 66.9% from its current price of $25.86.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $29.40 representing 100% downside risk from its current price of $25.86.
Fair Value
-
According to the consensus of 5 analysts, NewAmsterdam Pharma Co NV has 66.9% upside to fair value with a price target of $43.16 per share.
NAMS vs. S&P 500
-
Over the past 5 trading days, NewAmsterdam Pharma Co NV has overperformed the S&P 500 by 0.89% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
NewAmsterdam Pharma Co NV does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
NewAmsterdam Pharma Co NV has grown year-over-year revenues for 2 quarters straight. In the most recent quarter NewAmsterdam Pharma Co NV reported revenues of $29.1M.
Earnings Growth
-
NewAmsterdam Pharma Co NV has grown year-over-year earnings for 0 quarters straight. In the most recent quarter NewAmsterdam Pharma Co NV reported earnings per share of -$0.18.
Enterprise value:
2B
EV / Invested capital:
5.19x
Price / LTM sales:
69.34x
EV / EBIT:
--
EV / Revenue:
58.53x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-12.70x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-46.22%
Net Income Margin (TTM):
-592.12%
Return On Equity:
-51.66%
Return On Invested Capital:
-54.26%
Operating Margin:
-81.99%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | $33.6M | $2.9M | $29.1M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -$179.1M | -$48.3M | -$23.9M | |
| EBITDA | -- | -- | -$180.8M | -$48.3M | -$23.8M | |
| Diluted EPS | -- | -- | -$2.25 | -$0.57 | -$0.18 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | -- | $437.9M | |
| Total Assets | -- | -- | -- | -- | $439.2M | |
| Current Liabilities | -- | -- | -- | -- | $41.3M | |
| Total Liabilities | -- | -- | -- | -- | $60.3M | |
| Total Equity | -- | -- | -- | -- | $378.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -$154.2M | -$47M | -$12.5M | |
| Cash From Investing | -- | -- | -$672K | -$9K | -$75K | |
| Cash From Financing | -- | -- | $202.9M | $186K | $58K | |
| Free Cash Flow | -- | -- | -$154.8M | -$47M | -$12.6M | |
NAMS
Sector
Market Cap
$2.4B
$45.9M
Price % of 52-Week High
94.76%
46.95%
Dividend Yield
0%
0%
Shareholder Yield
-12.45%
-0.6%
1-Year Price Total Return
130.89%
-32.15%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$25.89
200-day SMA
Buy
Level
$19.65
Bollinger Bands (100)
Buy
Level
15.79 - 22.67
Chaikin Money Flow
Sell
Level
-50.6K
20-day SMA
Buy
Level
$23.30
Relative Strength Index (RSI14)
Buy
Level
62.41
ADX Line
Buy
Level
11.91
Williams %R
Sell
Level
-15.0844
50-day SMA
Buy
Level
$21.83
MACD (12, 26)
Buy
Level
1.40
25-day Aroon Oscillator
Buy
Level
16
On Balance Volume
Neutral
Level
4.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.5218)
Sell
CA Score
(Annual)
Level (-0.6846)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (3.9712)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
Stock Forecast FAQ
In the current month, NAMS has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NAMS average analyst price target in the past 3 months is $43.16.
-
Where Will NewAmsterdam Pharma Co NV Stock Be In 1 Year?
According to analysts, the consensus estimate is that NewAmsterdam Pharma Co NV share price will rise to $43.16 per share over the next 12 months.
-
What Do Analysts Say About NewAmsterdam Pharma Co NV?
Analysts are divided on their view about NewAmsterdam Pharma Co NV share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that NewAmsterdam Pharma Co NV is a Sell and believe this share price will drop from its current level to $29.40.
-
What Is NewAmsterdam Pharma Co NV's Price Target?
The price target for NewAmsterdam Pharma Co NV over the next 1-year time period is forecast to be $43.16 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NAMS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for NewAmsterdam Pharma Co NV is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NAMS?
You can purchase shares of NewAmsterdam Pharma Co NV via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase NewAmsterdam Pharma Co NV shares.
-
What Is The NewAmsterdam Pharma Co NV Share Price Today?
NewAmsterdam Pharma Co NV was last trading at $25.92 per share. This represents the most recent stock quote for NewAmsterdam Pharma Co NV. Yesterday, NewAmsterdam Pharma Co NV closed at $25.86 per share.
-
How To Buy NewAmsterdam Pharma Co NV Stock Online?
In order to purchase NewAmsterdam Pharma Co NV stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Coinbase Stock Going Down?
Every way you look at it, Coinbase has had a…
Is Uber Stock a Buy on the Dip?
Shares of Uber Technologies (NYSE:UBER) have been fading fast in…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
LMND alert for Dec 28
Lemonade [LMND] is down 10.69% over the past day.
Sell
50
TSLL alert for Dec 28
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 9.92% over the past day.
Buy
63
SMLR alert for Dec 28
Semler Scientific [SMLR] is down 9.65% over the past day.
